-- Cancer drug developer Juno Therapeutics rises 64.5 pct in debut
-- By Amrutha Gayathri in Bengaluru
-- Fri Dec 19, 2014 10:41AM EST
-- None



Dec 19 (Reuters) - Shares of Juno Therapeutics Inc <JUNO.O>, a biopharmaceutical company working on cancer treatments, rose as much as 64.5 percent in their market debut, valuing the company at about $3 billion.

The stock touched a high of $39.50 shortly after trading started on the Nasdaq on Friday. The initial public offering raised $264.5 million after the number of shares sold was increased to about 11 million from 9.3 million. The offering was priced at $24 per share, above the raised range of $21-$23. [ID:nBw4YzPTZa]